This is a commentary article using data reported by the United States Drug Approval (FDA) system for clinical trials. The text surmised reasons for this delay. The data show continued delay to impact drugs reaching patients. Instead of increasing drug approval, the statistics showed a trend of increased numbers of drug on hold. The reason for these delays need to be evaluated, and perhaps to apply new technologies to evaluate the data.